These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 5293638)

  • 1. [L-dopa treatment of Parkinson's disease].
    Chen KM
    Taiwan Yi Xue Hui Za Zhi; 1971 Jul; 70(7):424-30. PubMed ID: 5293638
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
    Kostrzewa RM; Kostrzewa JP; Brus R
    Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mechanisms of action of L-dopa in Parkinson's disease.
    Hornykiewicz O
    Life Sci; 1974 Oct; 15(7):1249-59. PubMed ID: 4620977
    [No Abstract]   [Full Text] [Related]  

  • 4. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
    Mercuri NB; Bernardi G
    Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.
    Cools R
    Neurosci Biobehav Rev; 2006; 30(1):1-23. PubMed ID: 15935475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluctuations in response to L-dopa in Parkinson's disease may be explained by changes in striatal dopamine turnover.
    Rose S; Thomas K; Jenner P; Marsden CD
    Br J Pharmacol; 1989 Dec; 98 Suppl():816P. PubMed ID: 2611523
    [No Abstract]   [Full Text] [Related]  

  • 7. Biochemical effects of chronic L-dopa treatment in rats: implications for emergence of tolerance phenomena in patients with Parkinson's disease.
    Melamed E; Globus M; Rosenthal J; Uzzan A
    Adv Neurol; 1987; 45():507-10. PubMed ID: 3825730
    [No Abstract]   [Full Text] [Related]  

  • 8. Dietary factors in the management of Parkinson's disease.
    Kempster PA; Wahlqvist ML
    Nutr Rev; 1994 Feb; 52(2 Pt 1):51-8. PubMed ID: 8183469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapy of Parkinson's disease.
    Cohen MM; Scheife RT
    Am J Hosp Pharm; 1977 May; 34(5):531-8. PubMed ID: 326045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L-dopa therapy for Parkinson's disease: past, present, and future.
    Nagatsua T; Sawadab M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S3-8. PubMed ID: 19131039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L-dopa in Parkinson's disease.
    Horstink MW; van de Vlasakker CJ
    Neurology; 1991 Oct; 41(10):1709. PubMed ID: 1922837
    [No Abstract]   [Full Text] [Related]  

  • 12. L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?
    Lipski J; Nistico R; Berretta N; Guatteo E; Bernardi G; Mercuri NB
    Prog Neurobiol; 2011 Sep; 94(4):389-407. PubMed ID: 21723913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parkinson's disease. The L-dopa era.
    Yahr MD
    Adv Neurol; 1993; 60():11-7. PubMed ID: 8420128
    [No Abstract]   [Full Text] [Related]  

  • 14. [Arguments in favor of the early treatment of Parkinson's disease with L-Dopa].
    Broussolle E
    Rev Neurol (Paris); 1999 Jan; 155(1):27-33. PubMed ID: 10093845
    [No Abstract]   [Full Text] [Related]  

  • 15. Levodopa in the early treatment of Parkinson's disease.
    Murata M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease.
    Riederer P; Gerlach M; Müller T; Reichmann H
    Parkinsonism Relat Disord; 2007 Dec; 13(8):466-79. PubMed ID: 17919963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Drug therapy in Parkinson's disease].
    van Hilten JJ; Roos RA
    Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What has been learnt from study of dopamine receptors in Parkinson's disease?
    Hurley MJ; Jenner P
    Pharmacol Ther; 2006 Sep; 111(3):715-28. PubMed ID: 16458973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Psychological changes in patients with Parkinson's disease during treatment with L-Dopa. Interpretation and comprehension of the observed phenomena].
    Fau R; Perret J; Israël L; Ohlmann T
    Ann Med Psychol (Paris); 1975 May; 1(5):670-83. PubMed ID: 1233896
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.